ArticleFrontiers in pharmacology2026
Chunghyul-dan, a multi-botanical ethanol extract, improves collateral perfusion and neurovascular stability in permanent focal cerebral ischemia.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Collateral perfusion and neurovascular stability critically influence outcomes after ischemic stroke; however, no pharmacological agent is currently approved to enhance these processes. Objectives: Chunghyul-dan (CHD), a standardized multi-botanical ethanol extract with reported vascular and anti-inflammatory properties, was evaluated for its neurovascular protective effects in a permanent middle cerebral artery occlusion (pMCAO) mouse model. The Process and Methods: Male ICR mice subjected to pMCAO received oral Chunghyul-dan (30-120 mg/kg). Cortical infarct volume, anterior cerebral artery perfusion, angiogenesis-related signaling, neuroinflammation, and endothelial barrier integrity were assessed using histological analysis, laser Doppler flowmetry, immunohistochemistry, and complementary Results: CHD significantly reduced cortical infarct volume, with maximal protection observed at 60 mg/kg. Laser Doppler analysis demonstrated enhanced ACA perfusion at 30 mg/kg during early ischemia. CHD upregulated VEGF expression in ischemic cortex and endothelial cells, supporting vascular remodeling. Neuroinflammation was attenuated, as CHD reduced Iba-1-positive microglial activation and suppressed iNOS, IL-6, and TNF-α expression. Endothelial barrier integrity was preserved through reduced PECAM-1 expression, restoration of claudin-5 and occludin, and selective inhibition of STAT3 phosphorylation, whereas TLR4/MAPK signaling remained unchanged. Conclusion: CHD confers multi-level neurovascular protection by promoting collateral perfusion, facilitating VEGF-associated vascular adaptation, suppressing neuroinflammation, and stabilizing endothelial junctional architecture. These findings support further translational evaluation of CHD as a pharmacological modulator of collateral circulation in ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.